Japanese Journal of Clinical Oncology Advance Access published online on June 16, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl044
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Thoracic Malignancy, Medical Center for Respiratory and Allergic Diseases of Osaka Prefecture, Osaka, Japan
* To whom correspondence should be addressed. Most patients with small cell lung cancer (SCLC) usually show relapse within 1 or 2 years. Relapses after a 5-year disease-free survival are extremely rare. This report describes two patients with stage I SCLC in whom the disease recurred 10 or more years after the start of initial therapy. Because the recurrence of SCLC was noted in the mediastinal lymph nodes of the same side, we concluded that the patients had a late relapse of SCLC rather than a metachronous lung cancer.
Received January 20, 2006
Accepted April 7, 2006
Case Report
Relapse of Stage I Small Cell Lung Cancer Ten or More Years after the Start of Treatment
Kaoru Matsui 1 *,
Toshiyuki Sawa 2,
Hidekazu Suzuki 1,
Katsuhiro Nakagawa 3,
Norio Okamoto 1,
Takuhito Tada 4,
Teruaki Nagano 5,
and
Noriyuki Masuda 6
2 Department of Thoracic Malignancy, Medical Center for Respiratory and Allergic Diseases of Osaka Prefecture, Osaka, Japan; Division of Respiratory Medicine, Gifu Municipal Hospital, Gifu, Japan
3 Department of Thoracic Surgery, Medical Center for Respiratory and Allergic Diseases of Osaka Prefecture, Osaka, Japan
4 Department of Radiology, Osaka City Medical School, Osaka, Japan
5 Department of pathology, Medical Center for Respiratory and Allergic Diseases of Osaka Prefecture, Osaka, Japan
6 Department of Respiratory Medicine, Kitasato University School of Medicine, Kanagawa, Japan
Kaoru Matsui, E-mail: kmatsui{at}hbk.pref.osaka.jp
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. W. L. Teng, J. B. Swann, C. M. Koebel, R. D. Schreiber, and M. J. Smyth Immune-mediated dormancy: an equilibrium with cancer J. Leukoc. Biol., October 1, 2008; 84(4): 988 - 993. [Abstract] [Full Text] [PDF] |
||||
